Keymed Biosciences advances Phase II trials for CM512 across multiple respiratory and inflammatory indications

PUBT · 2d ago
Keymed Biosciences advances Phase II trials for CM512 across multiple respiratory and inflammatory indications
  • Keymed’s CM512 was added to China’s Breakthrough Therapy Designation list, setting up accelerated regulatory engagement for chronic rhinosinusitis with nasal polyps.
  • A randomized, double-blind Phase II trial in CRSwNP will continue, with results to be released when appropriate.
  • Development plans also include advancing Phase II studies for CM512 across respiratory and immunology indications, including asthma and COPD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12253493), on July 23, 2026, and is solely responsible for the information contained therein.